Last reviewed · How we verify

Complete Insulin Orders

HealthPartners Institute · FDA-approved active Small molecule

Complete Insulin Orders is a clinical decision support program that optimizes insulin prescribing and dosing in healthcare settings.

Complete Insulin Orders is a clinical decision support program that optimizes insulin prescribing and dosing in healthcare settings. Used for Clinical decision support for insulin therapy optimization.

At a glance

Generic nameComplete Insulin Orders
Also known aslantus, glargine, humalog, lispro
SponsorHealthPartners Institute
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

This is not a pharmaceutical drug but rather a healthcare management program or protocol developed by HealthPartners Institute to standardize and improve insulin ordering practices. It likely provides clinical guidance on appropriate insulin selection, dosing, and administration to enhance glycemic control and patient safety in diabetes management.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: